Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody
by
Song, Jia-Cui
, Zhou, Nian-Yu
, He, Xian
, Wu, Qin
, Tang, Dan-Li
, Yin, Zhao-Fang
, Li, Hui-Ping
, Li, Nan
, Chen, Tao
, Chen, Shan-Shan
, Weng, Dong
, Qiu, Hui
, Zhao, Meng-Meng
, Lu, Li-Qin
in
Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF)
/ Antigens
/ Chromatography
/ Drug dosages
/ Hospitals
/ humanized surfactant protein-A (hSP-A)
/ humanized surfactant protein-A nanobody (SPANb)
/ Medicine
/ Proteins
/ Pulmonary fibrosis
/ Severe acute respiratory syndrome
/ Surfactants
2021
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody
by
Song, Jia-Cui
, Zhou, Nian-Yu
, He, Xian
, Wu, Qin
, Tang, Dan-Li
, Yin, Zhao-Fang
, Li, Hui-Ping
, Li, Nan
, Chen, Tao
, Chen, Shan-Shan
, Weng, Dong
, Qiu, Hui
, Zhao, Meng-Meng
, Lu, Li-Qin
in
Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF)
/ Antigens
/ Chromatography
/ Drug dosages
/ Hospitals
/ humanized surfactant protein-A (hSP-A)
/ humanized surfactant protein-A nanobody (SPANb)
/ Medicine
/ Proteins
/ Pulmonary fibrosis
/ Severe acute respiratory syndrome
/ Surfactants
2021
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody
by
Song, Jia-Cui
, Zhou, Nian-Yu
, He, Xian
, Wu, Qin
, Tang, Dan-Li
, Yin, Zhao-Fang
, Li, Hui-Ping
, Li, Nan
, Chen, Tao
, Chen, Shan-Shan
, Weng, Dong
, Qiu, Hui
, Zhao, Meng-Meng
, Lu, Li-Qin
in
Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF)
/ Antigens
/ Chromatography
/ Drug dosages
/ Hospitals
/ humanized surfactant protein-A (hSP-A)
/ humanized surfactant protein-A nanobody (SPANb)
/ Medicine
/ Proteins
/ Pulmonary fibrosis
/ Severe acute respiratory syndrome
/ Surfactants
2021
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody
Journal Article
Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody
2021
Request Book From Autostore
and Choose the Collection Method
Overview
Glucocorticoid (GC) hormone has been commonly used to treat systemic inflammation and immune disorders. However, the side effects associated with long-term use of high-dose GC hormone limit its clinical application seriously. GC hormone that can specifically target the lung might decrease the effective dosage and thus reduce GC-associated side effects. In this study, we successfully prepared human lung-targeting liposomal methylprednisolone crosslinked with nanobody (MPS-NSSLs-SPANb). Our findings indicate that MPS-NSSLs-SPANb may reduce the effective therapeutic dosage of MPS, achieve better efficacy, and reduce GC-associated side effects. In addition, MPS-NSSLs-SPANb showed higher efficacy and lower toxicity than conventional MPS.
Publisher
Taylor & Francis,Taylor & Francis Ltd,Taylor & Francis Group
Subject
This website uses cookies to ensure you get the best experience on our website.